Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multicenter, Phase II Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Progressed on Camrelizumab Combined With Apatinib

NCT06280105 is registered in ClinicalTrials.gov with Meng Chao Hepatobiliary Hospital of Fujian Medical University as lead sponsor.

NCT NCT06280105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06280105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multicenter, Phase II Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Progressed on Camrelizumab Combined With Apatinib
Lead sponsor
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
March 31, 2024
Completion date
March 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma